BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pirfenidone (AP01) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pirfenidone (AP01)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06329401-5990@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pirfenidone (AP01): Phase 2 readout est. (NCT06329401)
DESCRIPTION:Pirfenidone (AP01)\, phase 2.\nStudy: A Study Evaluating the Sa
 fety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmona
 ry Fibrosis\nEstimated primary completion: June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pirfenidone-ap01#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06329401
URL:https://assetmemo.bio/drug/pirfenidone-ap01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951217-5990@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pirfenidone (AP01): Phase 2 readout est. (NCT06951217)
DESCRIPTION:Pirfenidone (AP01)\, phase 2.\nStudy: An Extension Study of Sub
 jects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)\nEstimated 
 primary completion: 31 December 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pirfenidone-ap01#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06951217
URL:https://assetmemo.bio/drug/pirfenidone-ap01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
